Compare Aterian Inc (ATER) vs Danaher Corporation (DHR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Aterian Inc vs Danaher Corporation — how do they compare? Aterian Inc trades at $1.17 (market cap $12.98M), while Danaher Corporation trades at $199.47 (market cap $140.88B). The key difference: Danaher Corporation is far larger — about 10853.6× Aterian Inc's market cap, and Danaher Corporation pays a 0.8% dividend while Aterian Inc pays none. Which is the better fit depends on your goals.
| ATER | DHR | |
|---|---|---|
Market Cap | $12.98M | $140.88B |
Sector | Consumer Cyclical | Health |
52-Week High | $1.39 | $242.05 |
52-Week Low | $0.54 | $161.91 |
Enterprise Value | $13.56M | $153.66B |
Dividend Yield | — | 0.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aterian (ATER) trades at $1.19, up 3.48% with a bullish technical signal despite negative profitability. Recent earnings beats and a pending asset sale that could return $0.85-$1.14 per share provide near-term catalysts. However, the company shows declining revenue from $221M in 2022 to $69M in 2025, with negative net income margins and cash flow challenges.
The outlook hinges on shareholder approval of the brand portfolio sale, offering potential shareholder returns near current price levels. Investment opportunity exists in the asset sale catalyst, but risks include ongoing operational losses, declining revenue, and negative cash flow. Analyst sentiment is evenly split between Buy and Hold recommendations.
Danaher (DHR) trades at $199.05, showing minimal daily change, with a bullish technical signal supported by moving averages. The company maintains strong profitability with a 58.94% gross margin and has beaten earnings estimates for the last three quarters. Recent news highlights the acquisition of Masimo and new product launches in its SCIEX division, indicating growth initiatives. Cash flow improved in 2025 to a net inflow of $2.54 billion, though revenue growth remains modest.
The outlook is positive with a consensus price target of $211.33, representing a 6% upside, and 69% of analysts rate it a buy. Risks include slowing revenue growth, high valuation multiples, and integration challenges from acquisitions. The stock offers a dividend yield supported by stable cash flows, but investors should monitor competitive pressures in the life sciences sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Aterian Inc
Aterian Inc is a technology-enabled consumer products company. Its product categories include home and kitchen appliances, kitchenware, environmental appliances (dehumidifiers and air conditioners), beauty-related products, and consumer electronics. It has various owned and operated brands include Vremi, Healing Solutions, Xtava, TRUWEO, Spiralize, Pohl+Schmitt, and RIF6. The company generates revenue through the online sales of various consumer products that are sold online.
Read more on ATER →About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →
